A bill to amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

This bill creates a new definition for "currently accepted medical use with severe restrictions" under the Controlled Substances Act, applying only to specific drugs. It covers drugs designated as FDA breakthrough therapies or authorized for expanded patient access under strict conditions for serious diseases with no alternative treatments. The definition excludes FDA-approved drugs and drugs under clinical hold. The bill requires the Health Secretary to notify the Attorney General when such drugs qualify, triggering specific scheduling procedures and mandating reclassification within 90 days if the drug no longer meets the criteria.